?Product Name?: 5-Bromo-2-chlorobenzoic Acid
?CAS No.?: 21739-92-4

?? ?Product Overview?
A high-purity pharmaceutical intermediate widely used in synthesizing ?SGLT2 inhibitors? such as ?Dapagliflozin? and ?Empagliflozin?, key drugs for treating type 2 diabetes, heart failure, and chronic kidney disease?13. With a purity of ?≥98%? (HPLC), it ensures reliable quality for API production. Available in bulk quantities (1kg to 25kg) and compliant with global pharmaceutical standards?12.

?? ?Key Advantages?
? ?High Purity?: ≥98% (HPLC/GC-certified), ideal for API synthesis?14.
?? ?Flexible Packaging?: Customizable formats (1kg, 5kg, 25kg) for industrial and lab use?24.
?? ?Critical Role?: Key building block for SGLT2 inhibitors with a global market projected to grow at ?10.3% CAGR? (2025–2030)?35.

?? ?Applications?

1. ?Pharmaceutical Synthesis?: Core intermediate for ?Dapagliflozin (CAS 461432-26-8)? and ?Empagliflozin? production?13.

2. ?R&D?: Supports development of novel antidiabetic and cardiovascular therapies?35.

3. ?Export & Reagents?: Widely used in scientific research and chemical reagent markets?46.

?? ?Quality Certification?

• ?Testing Standards?: HPLC, GC, NMR, and mass spectrometry?12.

• ?Compliance?: Meets ISO 9001 and ICH Q7 guidelines for pharmaceutical intermediates?14.

?? ?Market Trends?
The demand for 5-Bromo-2-chlorobenzoic Acid is surging due to rising diabetes prevalence and expanded indications for SGLT2 inhibitors. Dapagliflozin alone holds approvals for ?3 major therapeutic areas?, driving API production growth?35. Asia-Pacific has emerged as a key manufacturing hub, with suppliers offering ?GMP-compliant batches? gaining strategic partnerships?13.